SA
ABBV icon

Strategic Advocates’s AbbVie ABBV Stock Holding History

Strategic Advocates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.74K Sell
31
-50
-62% -$11.1K 0.03% 169
2025
Q4 		$18.7K Buy
81
+10
+14% +$2.28K ﹤0.01% 296
2025
Q3 		$16.5K Buy
+71
New +$14.5K ﹤0.01% 307

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Strategic Advocates's ABBV Position: Q1 2026 in Review

Strategic Advocates reduced its AbbVie (ABBV) stake by 62% in Q1 2026, selling an estimated $11.1K and leaving 31 shares worth $6.74K. The position accounts for 0.03% of the portfolio, ranked #169.

Strategic Advocates first reported a position in ABBV in Q3 2025 and has held it in 3 quarters since. The position peaked at $18.7K in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Strategic Advocates held 31 shares of AbbVie worth $6.74K as of Q1 2026.
  • Strategic Advocates sold 50 AbbVie shares in Q1 2026, an estimated $11.1K.
  • AbbVie made up 0.03% of Strategic Advocates's portfolio in Q1 2026, its #169 holding.
  • Strategic Advocates first reported a position in AbbVie in Q3 2025 and has held it in 3 quarters since.
  • Strategic Advocates's AbbVie position peaked at $18.7K in Q4 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.